Suppr超能文献

26例原发性中枢神经系统淋巴瘤患者的临床表现及治疗结果

Clinical presentation and therapeutic outcome in 26 patients with primary CNS lymphoma.

作者信息

Herrlinger U, Schabet M, Clemens M, Kortmann R D, Petersen D, Will B E, Meyermann R, Dichgans J

机构信息

Department of Neurology, University of Tübingen, Germany.

出版信息

Acta Neurol Scand. 1998 Apr;97(4):257-64. doi: 10.1111/j.1600-0404.1998.tb00647.x.

Abstract

This retrospective study analyzes clinical features and therapeutic outcome in 26 immunocompetent patients with primary central nervous system lymphoma (PCNSL). Most patients presented with personality changes. PCNSL lesions were mainly iso- or hyperdense, enhancing lesions on CT scan, hypointensive on T1-, and hyperintensive on T2-weighted MRI. Multiple lesions were found in about 60% of patients. Nine of 11 patients receiving radiotherapy alone showed complete remission (CR). Median survival time after diagnosis (MST) was 13 months. Seven patients received intravenous and intrathecal methotrexate, radiotherapy, and postirradiation intravenous cytarabine. Six of these patients had CR and 5 patients are alive in CR after a median follow-up of 12 months. Five patients received various other radiochemotherapy regimens (MST 6 months), and 3 patients died before receiving any radio- or chemotherapy. Our preliminary treatment results show a tendency to improved survival with radiochemotherapy. This is consistent with pertinent data from the literature which favors radiochemotherapy for patients with PCNSL.

摘要

这项回顾性研究分析了26例免疫功能正常的原发性中枢神经系统淋巴瘤(PCNSL)患者的临床特征和治疗结果。大多数患者表现为性格改变。PCNSL病变在CT扫描上主要为等密度或高密度强化病变,在T1加权MRI上呈低信号,在T2加权MRI上呈高信号。约60%的患者发现有多处病变。11例仅接受放疗的患者中有9例完全缓解(CR)。诊断后的中位生存时间(MST)为13个月。7例患者接受了静脉和鞘内甲氨蝶呤、放疗以及放疗后静脉注射阿糖胞苷。这些患者中有6例完全缓解,中位随访12个月后,5例患者仍处于完全缓解状态存活。5例患者接受了其他各种放化疗方案(MST为6个月),3例患者在接受任何放疗或化疗之前死亡。我们的初步治疗结果显示放化疗有提高生存率的趋势。这与文献中的相关数据一致,文献支持对PCNSL患者采用放化疗。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验